Savara (SVRA) Other Non-Current Liabilities (2016 - 2026)
Savara (SVRA) posted quarterly Other Non-Current Liabilities of $44000.0 for Q1 2025, down 78.85% year-over-year from $208000.0 in Q1 2024, and down 49.43% quarter-over-quarter from $87000.0 in Q4 2024.
Savara (SVRA) Other Non-Current Liabilities (2016 - 2026) Analysis & Trends
Savara (SVRA) has reported Other Non-Current Liabilities for 10 consecutive years, with $44000.0 the latest figure, recorded in Q1 2025.
- In Q1 2025, Other Non-Current Liabilities fell 78.85% year-over-year to $44000.0; the TTM figure through Mar 2025 stood at $44000.0 (down 78.85% YoY), while the FY2024 annual figure was $87000.0, down 64.78% from the prior year.
- Other Non-Current Liabilities slipped to $44000.0 in Q1 2025 per SVRA's latest filing, from $87000.0 in the prior quarter.
- Across five years, Other Non-Current Liabilities topped out at $284000.0 in Q3 2023 and bottomed at $20000.0 in Q2 2023.
- Historically, Other Non-Current Liabilities has averaged $104823.5 across 5 years, with a median of $87000.0 in 2022.
- Annual changes were most pronounced in 2021 — Other Non-Current Liabilities sank 99.03% — and 2024, when it jumped 745.0%.
- Savara's Other Non-Current Liabilities stood at $117000.0 in 2021, then tumbled by 53.85% to $54000.0 in 2022, then soared by 357.41% to $247000.0 in 2023, then sank by 64.78% to $87000.0 in 2024, then slumped by 49.43% to $44000.0 in 2025.
- Business Quant data shows SVRA's Other Non-Current Liabilities at $44000.0 in Q1 2025, $87000.0 in Q4 2024, and $128000.0 in Q3 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Savara | 1.11 Bn | 1.11 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 770,000.00 |
| Mar 31, 2025 | 44,000.00 |
| Dec 31, 2024 | 87,000.00 |
| Sep 30, 2024 | 128,000.00 |
| Jun 30, 2024 | 169,000.00 |
| Mar 31, 2024 | 208,000.00 |
| Dec 31, 2023 | 247,000.00 |
| Sep 30, 2023 | 284,000.00 |
| Jun 30, 2023 | 20,000.00 |
| Mar 31, 2023 | 37,000.00 |
| Dec 31, 2022 | 54,000.00 |
| Sep 30, 2022 | 71,000.00 |
| Jun 30, 2022 | 87,000.00 |
| Mar 31, 2022 | 102,000.00 |
| Dec 31, 2021 | 117,000.00 |
| Sep 30, 2021 | 34,000.00 |
| Jun 30, 2021 | 35,000.00 |
| Mar 31, 2021 | 58,000.00 |
| Dec 31, 2020 | 84,000.00 |
| Sep 30, 2020 | 3.10 Mn |